Relation to Disease Severity and Prognosis in the Valsartan Heart Failure Trial

Background—Growth-differentiation factor-15 (GDF-15) is emerging as a prognostic biomarker in patients with coronary artery disease. Little is known about GDF-15 as a biomarker in patients with heart failure. Methods and Results—The circulating concentration of GDF-15 was measured at baseline (n 1734) and at 12 months (n 1517) in patients randomized in the Valsartan Heart Failure Trial (Val-HeFT). GDF-15 levels at baseline ranged from 259 to 25 637 ng/L and were abnormally high ( 1200 ng/L) in 85% of patients. Higher levels were associated with features of worse heart failure and biomarkers of neurohormonal activation, inflammation, myocyte injury, and renal dysfunction. Baseline GDF-15 levels (per 100 ng/L) were associated with the risks of mortality (hazard ratio, 1.017; 95% confidence interval, 1.014 to 1.019; P 0.001) and first morbid event (hazard ratio, 1.020; 95% confidence interval, 1.017 to 1.023; P 0.001). In a comprehensive multiple-variable Cox regression model that included clinical prognostic variables, B-type natriuretic peptide, high-sensitivity C-reactive protein, and high-sensitivity troponin T, GDF-15 remained independently associated with mortality (hazard ratio, 1.007; 95% confidence interval, 1.001 to 1.014; P 0.02) but not first morbid event. At 12 months, the GDF-15 levels had increased by a similar amount in the placebo and valsartan groups (P 0.94). Increases in GDF-15 over 12 months were independently associated with the risks of future mortality and first morbid event also after adjustment for clinical prognostic variables, B-type natriuretic peptide, high-sensitivity C-reactive protein, and high-sensitivity troponin T and their changes. Conclusions—GDF-15 reflects information from several pathological pathways and provides independent prognostic information in heart failure. GDF-15 levels increase over time, suggesting that GDF-15 reflects a pathophysiological axis that is not completely addressed by the therapies prescribed in Val-HeFT. (Circulation. 2010;122:1387-1395.)

[1]  L. Lind,et al.  Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. , 2009, European heart journal.

[2]  J. Cohn,et al.  C-Reactive Protein in Heart Failure: Prognostic Value and the Effect of Valsartan , 2005, Circulation.

[3]  D. Heudes,et al.  GDF15 triggers homeostatic proliferation of acid-secreting collecting duct cells. , 2008, Journal of the American Society of Nephrology : JASN.

[4]  D. Mozaffarian,et al.  The Seattle Heart Failure Model: Prediction of Survival in Heart Failure , 2006, Circulation.

[5]  J. Molkentin,et al.  STRESS signaling pathways that modulate cardiac myocyte apoptosis. , 2005, Journal of molecular and cellular cardiology.

[6]  Hugo A. Katus,et al.  Gene Expression Pattern in Biomechanically Stretched Cardiomyocytes: Evidence for a Stretch-Specific Gene Program , 2008, Hypertension.

[7]  G. Brabant,et al.  Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. , 2007, Clinical chemistry.

[8]  J. Cohn,et al.  Prognostic Value of Very Low Plasma Concentrations of Troponin T in Patients With Stable Chronic Heart Failure , 2007, Circulation.

[9]  J. Cohn,et al.  Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data. , 2004, Journal of the American College of Cardiology.

[10]  N. Hollenberg,et al.  Literature alert , 2002 .

[11]  A. Albini,et al.  Antiangiogenic Activity of the MDM2 Antagonist Nutlin-3 , 2007, Circulation research.

[12]  J. Hoheisel,et al.  Coronary disease; , 2004 .

[13]  W. D. Fairlie,et al.  Expression of growth differentiation factor‐15/ macrophage inhibitory cytokine‐1 (GDF‐15/MIC‐1) in the perinatal, adult, and injured rat brain , 2001, The Journal of comparative neurology.

[14]  M. Lapointe.  Molecular regulation of the brain natriuretic peptide gene , 2005, Peptides.

[15]  R. Schnabel,et al.  Growth-Differentiation Factor-15 for Risk Stratification in Patients With Stable and Unstable Coronary Heart Disease: Results From the AtheroGene Study , 2009, Circulation. Cardiovascular genetics.

[16]  T. Zimmers,et al.  GROWTH DIFFERENTIATION FACTOR-15/MACROPHAGE INHIBITORY CYTOKINE-1 INDUCTION AFTER KIDNEY AND LUNG INJURY , 2005, Shock.

[17]  Salim Yusuf,et al.  Predictors of mortality and morbidity in patients with chronic heart failure. , 2006, European heart journal.

[18]  R. Califf,et al.  Prognostic Value of Growth-Differentiation Factor-15 in Patients With Non–ST-Elevation Acute Coronary Syndrome , 2007, Circulation.

[19]  P. Ponikowski,et al.  Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. , 2007, Journal of the American College of Cardiology.

[20]  J. V. D. van den Ouweland,et al.  High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. , 2004, Clinical chemistry.

[21]  L. Fisher,et al.  Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT) , 2003, Circulation.

[22]  S. Silver,et al.  Heart Failure , 1937, The New England journal of medicine.

[23]  M. Frenneaux,et al.  Growth differentiation factor-15 predicts mortality and morbidity after cardiac resynchronization therapy , 2009, European heart journal.

[24]  J. Cohn,et al.  Proteinuria, Chronic Kidney Disease, and the Effect of an Angiotensin Receptor Blocker in Addition to an Angiotensin-Converting Enzyme Inhibitor in Patients With Moderate to Severe Heart Failure , 2009, Circulation.

[25]  T. Hewett,et al.  GDF15/MIC-1 Functions As a Protective and Antihypertrophic Factor Released From the Myocardium in Association With SMAD Protein Activation , 2006, Circulation research.

[26]  A. Siegbahn,et al.  Growth Differentiation Factor 15 for Risk Stratification and Selection of an Invasive Treatment Strategy in Non–ST-Elevation Acute Coronary Syndrome , 2007, Circulation.

[27]  K. Unsicker,et al.  Involvement of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in oxLDL-induced apoptosis of human macrophages in vitro and in arteriosclerotic lesions , 2004, Cell and Tissue Research.

[28]  A. Remppis,et al.  Reference change values and determinants of variability of NT-proANP and GDF15 in stable chronic heart failure , 2009, Basic Research in Cardiology.

[29]  K. Kos,et al.  Identification of macrophage inhibitory cytokine-1 in adipose tissue and its secretion as an adipokine by human adipocytes. , 2009, Endocrinology.

[30]  H. Drexler,et al.  The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. , 2006, Circulation research.

[31]  L. Wallentin,et al.  Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction. , 2007, European heart journal.

[32]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[33]  L. Koniaris,et al.  Characterization of Growth-Differentiation Factor 15, a Transforming Growth Factor β Superfamily Member Induced following Liver Injury , 2000, Molecular and Cellular Biology.

[34]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[35]  Cristina Opasich,et al.  Anemia and Change in Hemoglobin Over Time Related to Mortality and Morbidity in Patients With Chronic Heart Failure: Results From Val-HeFT , 2005, Circulation.

[36]  M. Drazner,et al.  B-type natriuretic peptide in cardiovascular disease , 2003, The Lancet.

[37]  G. Novo,et al.  Biomarkers in heart failure. , 2009, Frontiers in bioscience.

[38]  W. D. Fairlie,et al.  MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. , 1997, Proceedings of the National Academy of Sciences of the United States of America.